This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Articles

Dose Selection and Comparator Drugs in Schizophrenia Research

John M. Kane, MD

Published: August 1, 2001

Article Abstract

Dose selection and comparator drugs are important methodological issues in the evaluation of clinical data. Investigators rely heavily on dose selection in schizophrenia research, particularly when making comparisons between and across groups of compounds. In reality, however, the criteria for selecting a dose of drug in research trials are rather crude. Dosing and comparator issues vary enormously, depending on several factors. This article will discuss some of the dose-selection issues in schizophrenia research and the doses of antipsychotic drugs used in 5 recent comparative clinical trials.


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 62

Quick Links: Schizophrenia and Schizoaffective Disorders

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Young-Adult Social Outcomes of Attention-Deficit/Hyperactivity Disorder

ADHD that persisted into young-adulthood was associated with poorer outcomes in terms of education, employment, and emotional...

Read More...